416893-26-0

Upstream product

• 505-66-8 1,4-Diazacycloheptane 
• 109-01-3 1-methyl-piperazine 
• 4318-37-0 1-Methylhomopiperazine 
• 103-76-4 1-(2-hydroxyethyl)piperazine 
• 13349-82-1 1-[2-(2-hydroxyethoxy)ethyl]piperazine 
• 4897-50-1 4-piperidinopiperidin 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 2759-28-6 1-phenylmethylpiperazine 
• 303-26-4 N-(4-chlorobenzhydryl)piperazine 
• 51207-66-0 (S)-2-(1-pyrrolidinylmethyl)pyrrolidine 
• 103-55-9 N,N-dimethyl-N'-benzyl-1,2-ethanediamine 
• 5004-07-9 4-(1-pyrrolidinyl)piperidine 
• 2252-63-3 1-(4-Fluorophenyl)piperazine 
• 1011-15-0 1-(o-fluorophenyl)piperazine 

Relevant academic research and scientific papers

Synthesis and preliminary evaluation of anticonvulsant activity of some [4-(benzyloxy)benzoyl]-and [4-(benzyloxy)benzyl]aminoalkanol derivatives

A variety of appropriate [4-(benzyloxy)benzoyl]- and [4-(benzyloxy)benzyl] aminoalkanol derivatives [I-XVII] was synthesized and evaluated for anticonvulsant activity using the maximal electroshock (MES) and subcutaneous pentylenetetrazole (ScMet) tests in mice and rats. Neurotoxicity (TOX) was determined by the rotorod test. The most active compounds in the MES test in mice were the appropriate 4-(benzyloxy) benzyl derivatives of (R,S)- and S-(+)-2-amino-1-butanol [XI, XIII], 3-[4-(benzyloxy)benzyl]amino-3-methyl-1- butanol [XV], and S-(+)-2-[4-(benzyloxy)benzyl]amino-3-methyl-1-butanol [XVI] - all exhibiting 100% anti-MES protection (at 30 mg/kg, mice, i.p.) and non-toxic in the active doses. 4-[4-(Benzyloxy)benzyl]amino-1-butanol [X] exhibited activity in both MES and ScMet (100 mg/kg, mice, i.p., 100% anticonvulsant protection, 0.5 h and 4 h after administration, respectively).

METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS

Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising novel diamine compositions for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.